| performance |
phenotype |
3 |
— |
|
| Performance IQ |
phenotype |
3 |
2 |
PIQ, performance intelligence quotient |
| perinatal lethality |
phenotype |
4 |
1 |
die around birth |
| peripheral blood |
drug |
5 |
3 |
blood |
| perseveration |
phenotype |
2 |
1 |
|
| persistence |
phenotype |
2 |
— |
|
| personality disorders |
phenotype |
19 |
10 |
PD, PD instrument, PDs, personality disorders, personality disorders other than ASPD |
| personality traits |
phenotype |
37 |
20 |
FFM measure of personality traits, Five-Factor Model, major personality dimensions, personality, personality traits, psychological traits of interest |
| personalized medicine |
phenotype |
2 |
2 |
personalized medicine |
| pertussis toxin |
drug |
2 |
1 |
|
| PET |
drug |
2 |
2 |
positron emission tomography |
| PFA |
drug |
7 |
1 |
paraformaldehyde |
| p-factor |
phenotype |
7 |
2 |
general factor of liability for clinically-severe levels of psychopathology, general psychopathology factor, higher order p-factor, higher-order p-factor, p |
| Pfam |
drug |
3 |
— |
|
| PGC |
cohort |
21 |
16 |
PGC disorder working groups, PGC samples, PGC2 report, PGC3 standards, Psychiatric Genomics Consortium, Psychiatric Genomics Consortium Phase 2 |
| PGC AD |
cohort |
2 |
2 |
PGC, PGC Alcohol Dependence, Psychiatric Genomics Consortium AD |
| PGC GWAS |
cohort |
2 |
— |
Psychiatric Genomics Consortium GWAS |
| PGC meta-analysis |
cohort |
2 |
2 |
PGC meta-analyses |
| PGE2 |
drug |
3 |
2 |
Prostaglandin E2, prostaglandin E2 |
| PGK1 |
gene |
3 |
1 |
|
